PLEASANTON, Calif. - 10x Genomics, Inc. (NASDAQ: NASDAQ:TXG), known for its contributions to single cell and spatial biology, has commenced the shipment of its latest product, the Xenium Prime 5K Pan-Tissue and Pathways panel, as of today. This new assay is designed to significantly enhance gene analysis, boasting the ability to profile 5,000 genes and offering improvements in sensitivity, specificity, and spatial fidelity.
The Xenium Prime 5K panel is distinguished by its high plex, a term referring to the number of detectable genes in a single experiment, which has been increased by an order of magnitude compared to previous offerings. It is aimed at providing comprehensive profiling of cell types and states, as well as cell signaling pathways across various tissue and disease types. The panel is also customizable, allowing for the addition of up to 100 extra genes.
According to Ben Hindson, Co-Founder and Chief Scientific Officer at 10x Genomics, the new product has received positive feedback from early users, highlighting its performance across key metrics. The company emphasizes that this is its fifth major product launch this year, underscoring its commitment to innovation in the field.
The panel is designed with a rapid turnaround time, enabling researchers to analyze extensive tissue samples in less than a week. It is also compatible with a range of sample types, including fresh frozen and FFPE samples, facilitating a tissue-agnostic workflow.
10x Genomics has scheduled a webinar for June 25, 2024, to introduce the new panel to potential users. The company's products are used by researchers and biopharmaceutical companies to make strides in understanding biological systems and advancing human health, with applications in various fields such as oncology and neuroscience.
The information provided in this article is based on a press release statement from 10x Genomics.
In other recent news, 10x Genomics has been in the spotlight with several significant developments. The company's shareholders recently participated in a virtual annual meeting, electing Kimberly J. Popovits as a Class II director and ratifying Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2024. However, a proposal granting the board the power to amend the company's bylaws without stockholder approval did not pass. The company's executive compensation plan was approved in a non-binding, advisory vote.
ARK ETFs, managed by Cathie Wood, have shown a bullish stance on 10x Genomics, acquiring a substantial number of shares. Jefferies has also initiated coverage on the company with a Hold rating. ARK ETF's continued investment in 10x Genomics, along with Jefferies' coverage, suggests a positive outlook for the company among market analysts.
In product news, 10x Genomics announced the release of its new Xenium Prime 5K Pan-Tissue and Pathways panel, an advanced assay designed to enhance cellular pathways and biomarker studies.
InvestingPro Insights
As 10x Genomics (NASDAQ: TXG) continues to innovate with its latest product launch, the company's financial metrics and market performance provide additional context for potential investors. According to InvestingPro data, 10x Genomics currently holds a market capitalization of $2.37 billion. Despite the challenges in profitability, with an adjusted P/E ratio for the last twelve months as of Q1 2024 at -10.79, the company has demonstrated a solid revenue growth of 16.64% over the same period.
InvestingPro Tips suggest that 10x Genomics is trading near its 52-week low, with the price having fallen significantly over the last three months. This could potentially indicate a buying opportunity for investors who believe in the company's long-term value proposition and are looking for an entry point into the stock. Additionally, the Relative Strength Index (RSI) suggests that the stock is currently in oversold territory, which might attract those looking to capitalize on potential market corrections.
For investors seeking more detailed analysis, there are additional InvestingPro Tips available for 10x Genomics. For instance, while analysts have revised their earnings downwards for the upcoming period, the company's balance sheet reflects a positive position with more cash than debt, and liquid assets exceed short-term obligations. These financial nuances are crucial for a comprehensive investment decision-making process.
Interested readers can explore further insights and tips on 10x Genomics by visiting InvestingPro. For those looking to dive deeper into the company's analytics, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. Currently, InvestingPro offers a total of 12 additional tips for 10x Genomics, which could provide investors with a more nuanced understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.